CTRI/2010/091/000112招募中2 期
A Double-Blind, Randomized, Four Arm, Dose Ranging (Phase IIb) Study to Assess the Efficacy, Safety and Tolerability of Sertaconazole plus Secnidazole vaginal tablets in adult female patients with mixed vaginitis
Glenmark Pharmaceuticals Ltd0 个研究点目标入组 148 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 148
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Female patients with clinical [vaginal discharge/odor] & histopathologic diagnosis of mixed bacterial/fungal vaginitis, Age: 18 to 60 years; Non-pregnant (with negative Beta-human chorionic gonadotropin test) including breast feeding females; Patient willing to comply with study procedures and requirements
排除标准
- •Pregnant and nursing women, history of allergy to Sertaconazole and/or Secnidazole,Use of topical contraceptive preparations,Anticipation of menses during treatment,Any other condition that in the opinion of the investigator does not justify the patient's participation in the study.
研究者
相似试验
已完成
2 期
A clinical trial to study the effect, Safety and Tolerability of Crofelemer in the Treatment of Adult Acute Infectious DiarrheaCTRI/2009/091/000934Glenmark Pharmaceuticals Ltd200
招募中
3 期
Evaluation of Efficacy and Safety of Hydroxychloroquine in Patients with Type 2 DiabetesCTRI/2020/03/023714Ipca Laboratories Ltd
已完成
Unknown
Bioequivalence clinical trial to compare PK parameters and safety of Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) (Coageight, produced by AryoGen Pharmed Company) versus Elocta® in previously treated patients with severe hemophilia AIRCT20150303021315N31AryoGen Company50
已完成
不适用
Comparative Clinical Study on Collagen Peptide and resistant dextrin (nutritional supplements) in patients with type 2 diabetes mellitus.CTRI/2017/05/008464itta Gelatin India Limited60
进行中（未招募）
不适用
A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzheimer’s DiseaseEUCTR2008-004012-13-SKF. Hoffmann-La Roche Ltd360